Hospital
Tenet Hospitals Limited
Tenet Hospitals Limited was paid $21.72M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoTENET HOSPITALS LIMITED
EL PASO, TX 79938
EL PASO, TX 79938
33aNPI1972709970assigned 06/26/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.72M
24GClaims252,192
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#5 of 109
Median peer was paid$1.15M
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,393 | $152K | |
| 2019 | 1,409 | $80K | |
| 2020 | 7,158 | $320K | |
| 2021 | 59,151 | $4.07M | |
| 2022 | 83,860 | $7.42M | |
| 2023 | 69,021 | $6.79M | |
| 2024incomplete | 30,200 | $2.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 18,203 | 17,323 | $8.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 8,644 | 8,023 | $4.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 28,631 | 27,746 | $3.95M |
| 76819 | Fetal biophysical profile; without non-stress testing | 3.3% | 4,585 | 2,339 | $712K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.6% | 3,278 | 1,960 | $569K |
| 80053 | Comprehensive metabolic panel | 2.3% | 18,770 | 16,950 | $491K |
| 76820 | 1.9% | 4,425 | 2,191 | $414K | |
| 80050 | General health panel | 1.8% | 914 | 905 | $396K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 19,751 | 17,844 | $289K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 16,247 | 13,613 | $254K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 1,628 | 1,567 | $219K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,976 | 5,819 | $140K |
95 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 7,275 | $135K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,955 | $121K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,054 | $112K |
| 81001 | <1% | 12,894 | $98K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,747 | $91K |
| 80061 | Lipid panel | <1% | 1,570 | $88K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 265 | $83K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 699 | $82K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,589 | $75K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,039 | $71K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,762 | $69K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,718 | $66K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,276 | $64K |
| 93976 | <1% | 609 | $64K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,974 | $61K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,952 | $53K |
| 84439 | <1% | 1,026 | $50K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,302 | $36K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 323 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 748 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 504 | $27K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 85 | $24K |
| 84484 | <1% | 2,376 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 119 | $21K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 967 | $17K |
| 90715 | <1% | 193 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,338 | $16K |
| 83690 | <1% | 1,831 | $16K | |
| 87070 | <1% | 2,841 | $15K | |
| 81025 | <1% | 1,582 | $14K | |
| 83525 | <1% | 311 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 209 | $13K |
| 84702 | <1% | 1,013 | $13K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,896 | $11K |
| 87807 | <1% | 1,657 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,572 | $11K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 289 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 132 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 823 | $6K |
| 84703 | <1% | 472 | $6K | |
| 83880 | <1% | 288 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 83 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 359 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 365 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 178 | $5K |
| 82607 | <1% | 108 | $5K | |
| 81003 | <1% | 2,715 | $4K | |
| 87077 | <1% | 679 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 126 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,150 | $4K |
| 82728 | <1% | 103 | $4K | |
| 76827 | <1% | 30 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 620 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 87 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 41 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 502 | $3K |
| 85610 | <1% | 1,397 | $3K | |
| 87186 | <1% | 441 | $3K | |
| 83735 | <1% | 859 | $3K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 598 | $3K |
| 85730 | <1% | 835 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 725 | $2K |
| 80076 | <1% | 30 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 194 | $2K |
| 74018 | <1% | 131 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 405 | $2K |
| 86900 | <1% | 705 | $2K | |
| 86901 | <1% | 751 | $2K | |
| 85027 | <1% | 499 | $1K | |
| 0002A | <1% | 676 | $1K | |
| 99001 | <1% | 126 | $1K | |
| 87631 | <1% | 13 | $1K | |
| 76801 | <1% | 13 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 134 | $1K |
| 0001A | <1% | 705 | $978.97 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $868.35 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 772 | $806.99 |
| 85651 | <1% | 15 | $771.92 | |
| 82947 | <1% | 28 | $737.51 | |
| 82962 | <1% | 1,577 | $679.92 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $668.34 |
| 87806 | <1% | 12 | $602.03 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 81 | $489.88 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 74 | $489.42 |
| 90686 | <1% | 12 | $483.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,532 | $469.90 |
| 83605 | <1% | 108 | $436.72 | |
| 84100 | <1% | 243 | $389.60 | |
| G0008 | Administration of influenza virus vaccine | <1% | 27 | $342.60 |
| A9270 | Non-covered item or service | <1% | 1,415 | $66.06 |
| J2704 | Injection, propofol, 10 mg | <1% | 322 | $60.16 |
| 96376 | <1% | 19 | $31.90 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14 | $27.10 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 156 | $21.39 |
| 36416 | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORGAN, JESSICA (CFO)